Enhanced expression of interferon-inducible protein-10 correlates with disease activity and clinical manifestations in systemic lupus erythematosus

Clinical and Experimental Immunology

Volumn 156, Issue 1, 2009, Pages 134-140

  Kong, K O ^a   Tan, A W ^a   Thong, B Y H ^a   Lian, T Y ^a   Cheng, Y K ^a   Teh, C L ^a   Koh, E T ^a   Chng, H H ^a   Law, W G ^a   Lau, T C ^a   Leong, K P ^a   Leung, B P ^b   Howe, H S ^a  

^a TAN TOCK SENG HOSPITAL   (Singapore)

^b NATIONAL UNIVERSITY OF SINGAPORE   (Singapore)

Author keywords

Cytokine; Disease activity; IP 10; SLE

Indexed keywords

COMPLEMENT COMPONENT C3; COMPLEMENT COMPONENT C4; DOUBLE STRANDED DNA ANTIBODY; GAMMA INTERFERON INDUCIBLE PROTEIN 10; LIPOPOLYSACCHARIDE; MITOGENIC AGENT;

ADULT; ANTIBODY TITER; ARTICLE; CELL CULTURE; CLINICAL FEATURE; CONTROLLED STUDY; DISEASE ACTIVITY; DISEASE MARKER; ENZYME LINKED IMMUNOSORBENT ASSAY; ERYTHROCYTE SEDIMENTATION RATE; FEMALE; HUMAN; IN VITRO STUDY; MAJOR CLINICAL STUDY; MALE; PERIPHERAL BLOOD MONONUCLEAR CELL; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; PROTEIN EXPRESSION; PROTEIN SYNTHESIS; SYSTEMIC LUPUS ERYTHEMATOSUS;

ADULT; BIOLOGICAL MARKERS; CELLS, CULTURED; CHEMOKINE CXCL10; FEMALE; FOLLOW-UP STUDIES; HUMANS; LUPUS ERYTHEMATOSUS, SYSTEMIC; MALE; MIDDLE AGED; SENSITIVITY AND SPECIFICITY; SEVERITY OF ILLNESS INDEX; YOUNG ADULT;

EID: 61849179867     PISSN: 00099104     EISSN: 13652249     Source Type: Journal    
DOI: 10.1111/j.1365-2249.2009.03880.x     Document Type: Article

References (31)

1. Kammer GM, Perl A, Richardson BC, Tsokos GC. Abnormal T cell signal transduction in systemic lupus erythematosus. Arthritis Rheum 2002 46 : 1139 54.
2. Renaudineau Y, Pers JO, Bendaoud B, Jamin C, Youinou P. Dysfunctional B cells in systemic lupus erythematosus. Autoimmun Rev 2004 3 : 516 23.
3. Rönnblom L, Eloranta ML, Alm GV. The type I interferon system in systemic lupus erythematosus. Arthritis Rheum 2006 54 : 408 20.
4. Luster AD, Unkeless JC, Ravetch JV. Gamma-interferon transcriptionally regulates an early-response gene containing homology to platelet proteins. Nature 1985 315 : 672 6.
5. Neville LF, Mathiak G, Bagasra O. The immunobiology of interferon-gamma inducible protein 10 kD (IP-10): a novel, pleiotropic member of the C-X-C chemokine superfamily. Cytokine Growth Factor Rev 1997 8 : 207 19.
6. Padovan E, Spagnoli GC, Ferrantini M, Heberer M. IFN-alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. J Leukoc Biol 2002 71 : 669 76.
7. Christen U, von Herrath MG. IP-10 and type 1 diabetes: a question of time and location. Autoimmunity 2004 37 : 273 82.
8. Hanaoka R, Kasama T, Muramatsu M et al. A novel mechanism for the regulation of IFN-gamma inducible protein-10 expression in rheumatoid arthritis. Arthritis Res Ther 2003 5 : R74 81.
9. Azzurri A, Sow OY, Amedei A et al. IFN-gamma-inducible protein 10 and pentraxin 3 plasma levels are tools for monitoring inflammation and disease activity in Mycobacterium tuberculosis infection. Microbes Infect 2005 7 : 1 8.
10. Romero AI, Lagging M, Westin J, Dhillon AP, Dustin LB, Pawlotsky JM et al. Interferon (IFN)-γ-inducible protein-10: association with histological results, viral kinetics, and outcome during treatment with pegylated IFN-α2a and ribavirin for chronic hepatitis C virus infection. J Infect Dis 2006 194 : 895 903.
11. Shiozawa F, Kasama T, Yajima N et al. Enhanced expression of interferon-inducible protein 10 associated with Th1 profiles of chemokine receptor in autoimmune pulmonary inflammation of MRL/lpr mice. Arthritis Res Ther 2004 6 : R78 86.
12. Farkas L, Beiske K, Lund-Johansen F, Brandtzaeg P, Jahnsen FL. Plasmacytoid dendritic cells (natural interferon-alpha/beta-producing cells) accumulate in cutaneous lupus erythematosus lesions. Am J Pathol 2001 159 : 237 43.
13. Flier J, Boorsma DM, van Beek PJ et al. Differential expression of CXCR3 targeting chemokines CXCL10, CXCL9, and CXCL11 in different types of skin inflammation. J Pathol 2001 194 : 398 405.
14. Amoura Z, Combadiere C, Faure S et al. Roles of CCR2 and CXCR3 in the T cell-mediated response occurring during lupus flares. Arthritis Rheum 2003 48 : 3487 96.
15. Bauer JW, Baechler EC, Petri M et al. Elevated serum levels of interferon-regulated chemokines are biomarkers for active human systemic lupus erythematosus. PLoS Med 2006 3 : e491.
16. Eriksson C, Eneslatt K, Ivanoff J, Rantapaa-Dahlqvist S, Sundqvist KG. Abnormal expression of chemokine receptors on T-cells from patients with systemic lupus erythematosus. Lupus 2003 12 : 766 74.
17. Lit LC, Wong CK, Tam LS, Li EK, Lam CW. Raised plasma concentration and ex vivo production of inflammatory chemokines in patients with systemic lupus erythematosus. Ann Rheum Dis 2006 65 : 209 15.
18. Narumi S, Takeuchi T, Kobayashi Y, Konishi K. Serum levels of IFN-inducible protein-10 relating to the activity of systemic lupus erythematosus. Cytokine 2000 12 : 1561 5.
19. Hochberg MC. Updating the American College of Rheumatology revised criteria for the classification of systemic lupus erythematosus. Arthritis Rheum 1997 40 : 1725.
20. Liang MH, Socher SA, Larson MG, Schur PH. Reliability and validity of six systems for the clinical assessment of disease activity in systemic lupus erythematosus. Arthritis Rheum 1989 32 : 1107 18.
21. Abrahamowicz M, Fortin PR, du Berger R, Nayak V, Neville C, Liang MH. The relationship between disease activity and expert physician's decision to start major treatment in active systemic lupus erythematosus: a decision aid for development of entry criteria for clinical trials. J Rheumatol 1998 25 : 277 84.
22. Fortin PR, Abrahamowicz M, Clarke AE et al. Do lupus disease activity measures detect clinically important change? J Rheumatol 2000 27 : 1421 8.
23. Bertoli AM, Alarcon GS, McGwin G et al. Systemic lupus erythematosus in a multiethnic U.S. cohort (LUMINA) XXVII: factors predictive of a decline to low levels of disease activity. Lupus 2006 15 : 13 18.
24. Alarcon GS, Calvo-Alen J, McGwin G et al. Systemic lupus erythematosus in a multiethnic cohort: LUMINA XXXV. Predictive factors of high disease activity over time. Ann Rheum Dis 2006 65 : 1168 74.
25. Cuzick J. A Wilcoxon-type test for trend. Stat Med 1985 4 : 87 90.
26. Hanley JA, McNeil BJ. The meaning and use of the area under a receiver operating characteristic (ROC) curve. Radiology 1982 143 : 29 36.
27. Zeger SL, Liang KY, Albert PS. Models for longitudinal data: a generalized estimating equation approach. Biometrics 1988 44 : 1049 60.
28. Meller S, Winterberg F, Gilliet M et al. Ultraviolet radiation-induced injury, chemokines, and leukocyte recruitment: an amplification cycle triggering cutaneous lupus erythematosus. Arthritis Rheum 2005 52 : 1504 16.
29. Wenzel J, Worenkamper E, Freutel S et al. Enhanced type I interferon signalling promotes Th1-biased inflammation in cutaneous lupus erythematosus. J Pathol 2005 205 : 435 42.
30. Avihingsanon Y, Phumesin P, Benjachat T et al. Measurement of urinary chemokine and growth factor messenger RNAs: a noninvasive monitoring in lupus nephritis. Kidney Int 2006 69 : 747 53.
31. Illei GG, Tackey E, Lapteva L, Lipsky PE. Biomarkers in systemic lupus erythematosus. I. General overview of biomarkers and their applicability. Arthritis Rheum 2004 50 : 1709 20.